MicroRNA-491 regulates the proliferation and apoptosis of CD8 + T cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yu, Ting ^a   Zuo, Qian Fei ^a   Gong, Li ^a   Wang, Li Na ^a   Zou, Quan Ming ^a   Xiao, Bin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; GAMMA INTERFERON; MICRORNA; MIRN491 MICRORNA, MOUSE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; APOPTOSIS; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL CULTURE; COLORECTAL TUMOR; FEMALE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COLORECTAL NEOPLASMS; FEMALE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICRORNAS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84981724769     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30923     Document Type: Article

References (61)

1. Zhang, B. et al. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 68, 1563-1571, doi: 10.1158/0008-5472.CAN-07-5324 (2008)
2. Rusakiewicz, S. et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 73, 3499-3510, doi: 10.1158/0008-5472.CAN-13-0371 (2013)
3. Mahmoud, S. M. et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29, 1949-1955, doi: 10.1200/JCO.2010.30.5037 (2011)
4. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964, doi: 10.1126/science.1129139 (2006)
5. Flecken, T. et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology 59, 1415-1426, doi: 10.1002/hep.26731 (2014)
6. Rabinovich, G. A., Gabrilovich, D. & Sotomayor, E. M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296, doi: 10.1146/annurev.immunol.25.022106.141609 (2007)
7. Wherry, E. J. T cell exhaustion. Nat. Immunol. 131, 492-499, doi: 10.1038/ni.2035 (2011)
8. Schietinger, A. & Greenberg, P. D. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 35, 51-60, doi: 10.1016/j.it.2013.10.001 (2014)
9. Muljo, S. A. et al. Aberrant T cell differentiation in the absence of Dicer. J. Exp. Med. 202, 261-269, doi: 10.1084/jem.20050678 (2005)
10. Xiao, C. & Rajewsky, K. MicroRNA control in the immune system: basic principles. Cell 136, 26-36, doi: 10.1016/j.cell.2008.12.027 (2009)
11. Alvarez-Garcia, I. MicroRNA functions in animal development and human disease. Development 132, 4653-4662, doi: 10.1242/ dev.02073 (2005)
12. Yang, P. et al. TGF-ß -miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma. Cancer cell 22, 291-303, doi: 10.1016/j.ccr.2012.07.023 (2012)
13. Dudda, J. C. et al. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 38, 742-753, doi: 10.1016/j.immuni.2012.12.006 (2013)
14. Huffaker, T. B. et al. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell reports 2, 1697-1709, doi: 10.1016/j.celrep.2012.10.025 (2012)
15. Jiang, S. et al. Molecular dissection of the miR-17-92 clusters critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood 118, 5487-5497, doi: 10.1182/blood-2011-05-355644 (2011)
16. Huang, W. C. et al. miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis. Cancer Res. 74, 751-764, doi: 10.1158/0008-5472.CAN-13-1297 (2014)
17. Li, X. et al. Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene 34, 1619-1628, doi: 10.1038/onc.2014.98 (2015)
18. Denoyelle, C. et al. miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation. Cell Death Dis. 5, e1445, doi: 10.1038/cddis.2014.389 (2014)
19. Nakano, H., Miyazawa, T., Kinoshita, K., Yamada, Y. & Yoshida, T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int. J. Cancer 127, 1072-1080, doi: 10.1002/ijc.25143 (2010)
20. Leivonen, S.-K. et al. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol. Oncol. 8, 93-104, doi: 10.1016/j.molonc.2013.10.001 (2014)
21. Travis, M. A. & Sheppard, D. TGF-beta activation and function in immunity. Annu. Rev. Immunol. 32, 51-82, doi: 10.1146/annurevimmunol- 032713-120257 (2014)
22. Zhou, Q. et al. TGF-{beta}-induced MiR-491-5p expression promotes Par-3 degradation in rat proximal tubular epithelial cells. J. Biol. Chem. 285, 40019-40027, doi: 10.1074/jbc.M110.141341 (2010)
23. Cheng, L. et al. Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses. J. Hepatol. 61, 1297-1303, doi: 10.1016/j.jhep.2014.07.004 (2014)
24. Mlecnik, B. et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl. Med. 6, 228ra237, doi: 10.1126/scitranslmed.3007240 (2014)
25. Xu, F. et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res. 74, 3418-3428, doi: 10.1158/0008-5472.CAN-13-2690 (2014)
26. Lee do, Y. et al. 4-1BB signaling activates the t cell factor 1 effector/beta-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K/AKT activation to promote the proliferation of CD8+ T Cells. PLoS One 8, e69677, doi: 10.1371/journal.pone.0069677 (2013)
27. Zhou, X. et al. Differentiation and persistence of memory CD8(+ ) T cells depend on T cell factor 1. Immunity 33, 229-240, doi: 10.1016/j.immuni.2010.08.002 (2010)
28. Jeannet, G. et al. Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory. Proc. Natl. Acad. Sci. USA 107, 9777-9782, doi: 10.1073/pnas.0914127107 (2010)
29. Marrack, P. & Kappler, J. Control of T cell viability. Annu. Rev. Immunol. 22, 765-787, doi: 10.1146/annurev.immunol.22.012703.104554 (2004)
30. Li, W. et al. Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes. Mol. Cancer 14, 26, doi: 10.1186/s12943-014-0285-x (2015)
31. Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111, doi: 10.1038/35074122 (2001)
32. Sanjabi, S., Mosaheb, M. M. & Flavell, R. A. Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity 31, 131-144, doi: 10.1016/j.immuni.2009.04.020 (2009)
33. Tinoco, R., Alcalde, V., Yang, Y., Sauer, K. & Zuniga, E. I. Cell-intrinsic transforming growth factor-beta signaling mediates virusspecific CD8+ T cell deletion and viral persistence in vivo. Immunity 31, 145-157, doi: 10.1016/j.immuni.2009.06.015 (2009)
34. Yang, L., Pang, Y. & Moses, H. L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31, 220-227, doi: 10.1016/j.it.2010.04.002 (2010)
35. Butz, H., Racz, K., Hunyady, L. & Patocs, A. Crosstalk between TGF-beta signaling and the microRNA machinery. Trends Pharmacol. Sci. 33, 382-393, doi: 10.1016/j.tips.2012.04.003 (2012)
36. Wang, Y. et al. Regulation of T cell function by microRNA-720. Sci. Rep. 5, 12159, doi: 10.1038/srep12159 (2015)
37. Chandran, P. A. et al. The TGF-beta-inducible miR-23a cluster attenuates IFN-gamma levels and antigen-specific cytotoxicity in human CD8(+ ) T cells. J. Leukoc. Biol. 96, 633-645, doi: 10.1189/jlb.3A0114-025R (2014)
38. Lin, R. et al. Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J. Clin. Invest. 124, 5352-5367, doi: 10.1172/JCI76561 (2014)
39. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133, doi: 10.1056/ NEJMoa1302369 (2013)
40. Kvistborg, P. et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl. Med. 6, 254ra128, doi: 10.1126/scitranslmed.3008918 (2014)
41. Callahan, M. K. & Wolchok, J. D. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J. Leukoc. Biol. 94, 41-53, doi: 10.1189/jlb.1212631 (2013)
42. Hailemichael, Y. et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+ ) T cell sequestration, dysfunction and deletion. Nat. Med. 19, 465-472, doi: 10.1038/nm.3105 (2013)
43. Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239, doi: 10.1200/JCO.2008.16.5449 (2008)
44. Ji, Y. et al. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic gammac cytokines. Proc. Natl. Acad. Sci. USA 112, 476-481, doi: 10.1073/pnas.1422916112 (2015)
45. Guinn, D. et al. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Brutons tyrosine kinase inhibition with Ibrutinib. Leukemia 29, 1210-1213, doi: 10.1038/leu.2014.344 (2015)
46. Lin, R., Sampson, J. H., Li, Q. J. & Zhu, B. miR-23a blockade enhances adoptive T cell transfer therapy by preserving immunecompetence in the tumor microenvironment. Oncoimmunology 4, e990803, doi: 10.4161/2162402X.2014.990803 (2015)
47. Xu, H., Cheung, I. Y., Guo, H. F. & Cheung, N. K. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 69, 6275-6281, doi: 10.1158/0008-5472.CAN- 08-4517 (2009)
48. Ghisi, M. et al. Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood 117, 7053-7062, doi: 10.1182/blood-2010-12-326629 (2011)
49. Smith, N. L., Wissink, E. M., Grimson, A. & Rudd, B. D. miR-150 Regulates Differentiation and Cytolytic Effector Function in CD8+ T cells. Sci. Rep. 5, 16399, doi: 10.1038/srep16399 (2015)
50. Khan, A. A., Penny, L. A., Yuzefpolskiy, Y., Sarkar, S. & Kalia, V. MicroRNA-17~92 regulates effector and memory CD8 T-cell fates by modulating proliferation in response to infections. Blood 121, 4473-4483, doi: 10.1182/blood-2012-06-435412 (2013)
51. Wu, T. et al. Temporal expression of microRNA cluster miR-17-92 regulates effector and memory CD8+ T-cell differentiation. Proc. Natl. Acad. Sci. USA 109, 9965-9970, doi: 10.1073/pnas.1207327109 (2012)
52. Wu, Y. et al. MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. Blood 126, 1314-1323, doi: 10.1182/blood-2015-02-627356 (2015)
53. Zhang, N. & Bevan, M. J. Dicer controls CD8+ T-cell activation, migration, and survival. Proc. Natl. Acad. Sci. USA 107, 21629-21634, doi: 10.1073/pnas.1016299107 (2010)
54. Trifari, S. et al. MicroRNA-directed program of cytotoxic CD8+ T-cell differentiation. Proc. Natl. Acad. Sci. USA 110, 18608-18613, doi: 10.1073/pnas.1317191110 (2013)
55. Zhao, E. et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat. Immunol. 17, 95-103, doi: 10.1038/ni.3313 (2015)
56. Zhang, Z. N. et al. Transcriptomic analysis of peripheral blood mononuclear cells in rapid progressors in early HIV infection identifies a signature closely correlated with disease progression. Clin. Chem. 59, 1175-1186, doi: 10.1373/clinchem.2012.197335 (2013)
57. Jindra, P. T., Bagley, J., Godwin, J. G. & Iacomini, J. Costimulation-dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting Pten. J. Immunol. 185, 990-997, doi: 10.4049/jimmunol.1000793 (2010)
58. Cheng, N. L. et al. MicroRNA-125b modulates inflammatory chemokine CCL4 expression in immune cells and its reduction causes CCL4 increase with age. Aging cell 14, 200-208, doi: 10.1111/acel.12294 (2015)
59. Wei, J. et al. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol., doi: 10.1093/neuonc/nov292 (2015)
60. Wang, X. et al. Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491. Toxicol. Lett. 227, 75-83, doi: 10.1016/j.toxlet.2014.03.016 (2014)
61. Lu, L. F. et al. A Single miRNA-mRNA Interaction Affects the Immune Response in a Context- and Cell-Type-Specific Manner. Immunity 43, 52-64, doi: 10.1016/j.immuni.2015.04.022 (2015)